Combination therapy before stem cell transplant for Ph+ ALL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two targeted drugs given before a stem cell transplant for people with a specific type of acute lymphoblastic leukemia (Ph+ ALL) that did not fully respond to initial treatment. The goal is to make the leukemia undetectable before transplant, which may improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of Ph+ ALL (Philadelphia chromosome positive or BCR-ABL positive) with CD22 on the leukemia cells.
- Your leukemia must have remained detectable (MRD positive) after your first chemotherapy combined with a targeted therapy (TKI).
- Your liver, kidney, pancreas, and heart function must be adequate (your doctor will check this).
- You must not have HIV, hepatitis B or C, or other serious medical conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted pill (olverembatinib) given after a stem cell transplant to help prevent leukemia from coming back in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It may also be used early if signs of the disease appear.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
This trial tests two medicines together: olverembatinib (a pill) and blinatumomab (given by infusion). It is for people who are newly diagnosed with Ph+ ALL and have not had chemotherapy yet. The goal is to see if this combination works well and is safe.
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.